GlassScriptPhysician profile
Sean M Mcwilliams
NPI 1003854803
$5,282.43
in general payments reported to CMS, 2019-2025
6 companies · $5,021 in 2025
The $5,021 reported for 2025 was more than what 95% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $262 · 2025: $5,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,158 · Food and Beverage: $1,100 · Travel and Lodging: $990 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,158.34 |
| Food and Beverage | $1,099.60 |
| Travel and Lodging | $990.49 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spirair, INC. | $3,225.76 | 2025 | Septalign, Turbalign |
| Medtronic, INC. | $1,787.64 | 2024-2025 | Nuvent, Propel |
| Genzyme Corporation | $130.75 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $87.55 | 2025 | Dupixent |
| Amgen INC. | $34.00 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $16.73 | 2025 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$48,598.56 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Mcwilliams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.